-
1
-
-
81255160848
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
-
22015057 10.1016/S1470-2045(11)70266-2 1:CAS:528:DC%2BC3MXhsVSktrnK
-
Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martinez E, Moreno F, Font A, Robledo M, Rodriguez-Antona C (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143-1150
-
(2011)
Lancet Oncol
, vol.12
, pp. 1143-1150
-
-
Garcia-Donas, J.1
Esteban, E.2
Leandro-Garcia, L.J.3
Castellano, D.E.4
Del Alba, A.G.5
Climent, M.A.6
Arranz, J.A.7
Gallardo, E.8
Puente, J.9
Bellmunt, J.10
Mellado, B.11
Martinez, E.12
Moreno, F.13
Font, A.14
Robledo, M.15
Rodriguez-Antona, C.16
-
2
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
19487381 10.1200/JCO.2008.20.1293 1:CAS:528:DC%2BD1MXhtVOnu7nI
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590
-
(2009)
J Clin Oncol
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Oudard, S.6
Negrier, S.7
Szczylik, C.8
Pili, R.9
Bjarnason, G.A.10
Garcia-Del-Muro, X.11
Sosman, J.A.12
Solska, E.13
Wilding, G.14
Thompson, J.A.15
Kim, S.T.16
Chen, I.17
Huang, X.18
Figlin, R.A.19
-
3
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
4
-
-
77954024679
-
An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma
-
10.1016/S1359-6349(09)71451-X
-
Lee SCH, Mainwaring P, Ng C, Chang JWC, Kwong P et al (2009) An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Suppl (abstract) 7:428
-
(2009)
Eur J Cancer Suppl (Abstract)
, vol.7
, pp. 428
-
-
Lee, S.C.H.1
Mainwaring, P.2
Ng, C.3
Chang, J.W.C.4
Kwong, P.5
-
5
-
-
77957272015
-
Wahid MI Kidney cancer working group report
-
Naito S, Tomita Y, Rha SY, Uemura H, Oya M, Song HZ, Zhong LH (2010) Wahid MI Kidney cancer working group report. Jpn J Clin Oncol 40(Suppl 1):i51-i56
-
(2010)
Jpn J Clin Oncol
, vol.40
, Issue.SUPPL. 1
-
-
Naito, S.1
Tomita, Y.2
Rha, S.Y.3
Uemura, H.4
Oya, M.5
Song, H.Z.6
Zhong, L.H.7
-
6
-
-
79961102885
-
Sunitinib for Asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles
-
21829041 10.1159/000330361 1:CAS:528:DC%2BC3MXhtFCls7fK
-
Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, Lee SH, Bang YJ, Rha SY (2011) Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 80:395-405
-
(2011)
Oncology
, vol.80
, pp. 395-405
-
-
Kim, H.S.1
Hong, M.H.2
Kim, K.3
Shin, S.J.4
Ahn, J.B.5
Jeung, H.C.6
Chung, H.C.7
Koh, Y.8
Lee, S.H.9
Bang, Y.J.10
Rha, S.Y.11
-
7
-
-
78649581750
-
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma
-
20713418 10.1093/jjco/hyq146
-
Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166-1172
-
(2010)
Jpn J Clin Oncol
, vol.40
, pp. 1166-1172
-
-
Tomita, Y.1
Shinohara, N.2
Yuasa, T.3
Fujimoto, H.4
Niwakawa, M.5
Mugiya, S.6
Miki, T.7
Uemura, H.8
Nonomura, N.9
Takahashi, M.10
Hasegawa, Y.11
Agata, N.12
Houk, B.13
Naito, S.14
Akaza, H.15
-
8
-
-
77953789493
-
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: A single cancer center experience in Korea
-
19707503 10.4143/crt.2009.41.2.67
-
Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY (2009) Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 41:67-72
-
(2009)
Cancer Res Treat
, vol.41
, pp. 67-72
-
-
Hong, M.H.1
Kim, H.S.2
Kim, C.3
Ahn, J.R.4
Chon, H.J.5
Shin, S.J.6
Ahn, J.B.7
Chung, H.C.8
Rha, S.Y.9
-
9
-
-
48249107432
-
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
-
18594533 10.1038/sj.bjc.6604456
-
van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259-265
-
(2008)
Br J Cancer
, vol.99
, pp. 259-265
-
-
Van Der Veldt, A.A.1
Boven, E.2
Helgason, H.H.3
Van Wouwe, M.4
Berkhof, J.5
De Gast, G.6
Mallo, H.7
Tillier, C.N.8
Van Den Eertwegh, A.J.9
Haanen, J.B.10
-
10
-
-
78549246206
-
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
-
Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A (2010) Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 28:866-875
-
(2010)
Invest New Drugs
, vol.28
, pp. 866-875
-
-
Shirao, K.1
Nishida, T.2
Doi, T.3
Komatsu, Y.4
Muro, K.5
Li, Y.6
Ueda, E.7
Ohtsu, A.8
-
11
-
-
34548598185
-
Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
-
17285315 10.1007/s00280-007-0427-6 1:CAS:528:DC%2BD2sXhtVWqtbfO
-
Guo F, Letrent SP, Sharma A (2007) Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Cancer Chemother Pharmacol 60:799-809
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 799-809
-
-
Guo, F.1
Letrent, S.P.2
Sharma, A.3
-
12
-
-
36048936308
-
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
-
17947717 10.1200/JCO.2007.11.2938 1:CAS:528:DC%2BD2sXhtlCgsLjJ
-
Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25:4707-4713
-
(2007)
J Clin Oncol
, vol.25
, pp. 4707-4713
-
-
Sparreboom, A.1
Wolff, A.C.2
Mathijssen, R.H.3
Chatelut, E.4
Rowinsky, E.K.5
Verweij, J.6
Baker, S.D.7
-
13
-
-
65249087328
-
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
-
19258444 10.1158/1078-0432.CCR-08-1893 1:CAS:528:DC%2BD1MXjvVWksLg%3D
-
Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497-2506
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2497-2506
-
-
Houk, B.E.1
Bello, C.L.2
Kang, D.3
Amantea, M.4
-
14
-
-
70349342710
-
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
-
19667267 10.1200/JCO.2008.21.7679
-
van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406-4412
-
(2009)
J Clin Oncol
, vol.27
, pp. 4406-4412
-
-
Van Erp, N.P.1
Eechoute, K.2
Van Der Veldt, A.A.3
Haanen, J.B.4
Reyners, A.K.5
Mathijssen, R.H.6
Boven, E.7
Van Der Straaten, T.8
Baak-Pablo, R.F.9
Wessels, J.A.10
Guchelaar, H.J.11
Gelderblom, H.12
-
15
-
-
20044365778
-
Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface
-
15557326 10.1074/jbc.M411338200
-
Ozvegy-Laczka C, Varady G, Koblos G, Ujhelly O, Cervenak J, Schuetz JD, Sorrentino BP, Koomen GJ, Varadi A, Nemet K, Sarkadi B (2005) Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface. J Biol Chem 280:4219-4227
-
(2005)
J Biol Chem
, vol.280
, pp. 4219-4227
-
-
Ozvegy-Laczka, C.1
Varady, G.2
Koblos, G.3
Ujhelly, O.4
Cervenak, J.5
Schuetz, J.D.6
Sorrentino, B.P.7
Koomen, G.J.8
Varadi, A.9
Nemet, K.10
Sarkadi, B.11
-
16
-
-
20444393495
-
Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters
-
15939339 10.1016/j.drup.2005.02.002
-
Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B (2005) Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat 8:15-26
-
(2005)
Drug Resist Updat
, vol.8
, pp. 15-26
-
-
Ozvegy-Laczka, C.1
Cserepes, J.2
Elkind, N.B.3
Sarkadi, B.4
-
17
-
-
2442638937
-
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
-
15155841 10.1124/mol.65.6.1485
-
Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485-1495
-
(2004)
Mol Pharmacol
, vol.65
, pp. 1485-1495
-
-
Ozvegy-Laczka, C.1
Hegedus, T.2
Varady, G.3
Ujhelly, O.4
Schuetz, J.D.5
Varadi, A.6
Keri, G.7
Orfi, L.8
Nemet, K.9
Sarkadi, B.10
-
18
-
-
25144450089
-
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps
-
15970668 10.4161/cbt.4.7.1826 1:CAS:528:DC%2BD28XjtlWktLc%3D
-
Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K (2005) Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4:747-752
-
(2005)
Cancer Biol Ther
, vol.4
, pp. 747-752
-
-
Burger, H.1
Van Tol, H.2
Brok, M.3
Wiemer, E.A.4
De Bruijn, E.A.5
Guetens, G.6
De Boeck, G.7
Sparreboom, A.8
Verweij, J.9
Nooter, K.10
-
19
-
-
23044449295
-
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein
-
16061679 10.1158/0008-5472.CAN-05-0641 1:CAS:528:DC%2BD2MXmvFSlurk%3D
-
Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65:6943-6949
-
(2005)
Cancer Res
, vol.65
, pp. 6943-6949
-
-
Yang, C.H.1
Huang, C.J.2
Yang, C.S.3
Chu, Y.C.4
Cheng, A.L.5
Whang-Peng, J.6
Yang, P.C.7
-
20
-
-
33646404611
-
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo
-
16651435 10.1158/0008-5472.CAN-05-2915 1:CAS:528:DC%2BD28XjvF2kt78%3D
-
Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF (2006) Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66:4802-4807
-
(2006)
Cancer Res
, vol.66
, pp. 4802-4807
-
-
Leggas, M.1
Panetta, J.C.2
Zhuang, Y.3
Schuetz, J.D.4
Johnston, B.5
Bai, F.6
Sorrentino, B.7
Zhou, S.8
Houghton, P.J.9
Stewart, C.F.10
-
21
-
-
34249669336
-
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
-
17519960 10.1038/sj.leu.2404638 1:CAS:528:DC%2BD2sXlsFOiu7o%3D
-
Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21:1267-1275
-
(2007)
Leukemia
, vol.21
, pp. 1267-1275
-
-
Brendel, C.1
Scharenberg, C.2
Dohse, M.3
Robey, R.W.4
Bates, S.E.5
Shukla, S.6
Ambudkar, S.V.7
Wang, Y.8
Wennemuth, G.9
Burchert, A.10
Boudriot, U.11
Neubauer, A.12
-
22
-
-
40349098162
-
Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors
-
18253130 10.1038/sj.bjc.6604213 1:CAS:528:DC%2BD1cXivVOgt7o%3D
-
Lemos C, Jansen G, Peters GJ (2008) Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 98:857-862
-
(2008)
Br J Cancer
, vol.98
, pp. 857-862
-
-
Lemos, C.1
Jansen, G.2
Peters, G.J.3
-
23
-
-
70649110001
-
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin
-
19842935 10.2217/pgs.09.85 1:CAS:528:DC%2BD1MXht12msbrN
-
Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M (2009) Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617-1624
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1617-1624
-
-
Keskitalo, J.E.1
Pasanen, M.K.2
Neuvonen, P.J.3
Niemi, M.4
-
24
-
-
79951937698
-
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
-
Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ (2011) Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 12:159-170
-
(2011)
Pharmacogenomics
, vol.12
, pp. 159-170
-
-
Lemos, C.1
Giovannetti, E.2
Zucali, P.A.3
Assaraf, Y.G.4
Scheffer, G.L.5
Van Der Straaten, T.6
D'Incecco, A.7
Falcone, A.8
Guchelaar, H.J.9
Danesi, R.10
Santoro, A.11
Giaccone, G.12
Tibaldi, C.13
Peters, G.J.14
-
25
-
-
78449308869
-
ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: Analysis and a comprehensive comparison with other populations
-
21054463 10.1111/j.1365-2710.2009.01127.x
-
Kim KA, Joo HJ, Park JY (2010) ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations. J Clin Pharm Ther 35:705-712
-
(2010)
J Clin Pharm Ther
, vol.35
, pp. 705-712
-
-
Kim, K.A.1
Joo, H.J.2
Park, J.Y.3
-
26
-
-
1442290393
-
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
-
14752067 10.1200/JCO.2004.06.132
-
Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463
-
(2004)
J Clin Oncol
, vol.22
, pp. 454-463
-
-
Motzer, R.J.1
Bacik, J.2
Schwartz, L.H.3
Reuter, V.4
Russo, P.5
Marion, S.6
Mazumdar, M.7
-
27
-
-
13444269543
-
Haploview: Analysis and visualization of LD and haplotype maps
-
15297300 10.1093/bioinformatics/bth457 1:CAS:528:DC%2BD2MXkt1WitQ%3D%3D
-
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
-
(2005)
Bioinformatics
, vol.21
, pp. 263-265
-
-
Barrett, J.C.1
Fry, B.2
Maller, J.3
Daly, M.J.4
-
28
-
-
77953967726
-
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
-
20348146 10.1093/annonc/mdq150 1:STN:280:DC%2BC3czmtFSjsA%3D%3D
-
Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, Inui K (2010) ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 21:1382-1383
-
(2010)
Ann Oncol
, vol.21
, pp. 1382-1383
-
-
Mizuno, T.1
Terada, T.2
Kamba, T.3
Fukudo, M.4
Katsura, T.5
Nakamura, E.6
Ogawa, O.7
Inui, K.8
-
29
-
-
65249087328
-
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
-
19258444 10.1158/1078-0432.CCR-08-1893 1:CAS:528:DC%2BD1MXjvVWksLg%3D
-
Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497-2506
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2497-2506
-
-
Houk, B.E.1
Bello, C.L.2
Kang, D.3
Amantea, M.4
-
30
-
-
59649129538
-
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2
-
18971320 10.1124/dmd.108.024612 1:CAS:528:DC%2BD1MXhs1Krsbo%3D
-
Shukla S, Robey RW, Bates SE, Ambudkar SV (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37:359-365
-
(2009)
Drug Metab Dispos
, vol.37
, pp. 359-365
-
-
Shukla, S.1
Robey, R.W.2
Bates, S.E.3
Ambudkar, S.V.4
-
31
-
-
0036598543
-
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance
-
12479221 1:CAS:528:DC%2BD38XlsFSlsr4%3D
-
Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 611-616
-
-
Imai, Y.1
Nakane, M.2
Kage, K.3
Tsukahara, S.4
Ishikawa, E.5
Tsuruo, T.6
Miki, Y.7
Sugimoto, Y.8
-
32
-
-
79951937698
-
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
-
21332310 10.2217/pgs.10.172 1:CAS:528:DC%2BC3MXitFeitLk%3D
-
Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ (2011) Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 12:159-170
-
(2011)
Pharmacogenomics
, vol.12
, pp. 159-170
-
-
Lemos, C.1
Giovannetti, E.2
Zucali, P.A.3
Assaraf, Y.G.4
Scheffer, G.L.5
Van Der Straaten, T.6
D'Incecco, A.7
Falcone, A.8
Guchelaar, H.J.9
Danesi, R.10
Santoro, A.11
Giaccone, G.12
Tibaldi, C.13
Peters, G.J.14
-
33
-
-
34547779489
-
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins
-
17605814 10.1186/1479-5876-5-32
-
Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32
-
(2007)
J Transl Med
, vol.5
, pp. 32
-
-
Deprimo, S.E.1
Bello, C.L.2
Smeraglia, J.3
Baum, C.M.4
Spinella, D.5
Rini, B.I.6
Michaelson, M.D.7
Motzer, R.J.8
-
34
-
-
33646445341
-
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
-
16606972 10.1200/JCO.2005.04.1665 1:CAS:528:DC%2BD28Xlt1amur0%3D
-
Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027
-
(2006)
J Clin Oncol
, vol.24
, pp. 2019-2027
-
-
Bear, H.D.1
Anderson, S.2
Smith, R.E.3
Geyer, Jr.C.E.4
Mamounas, E.P.5
Fisher, B.6
Brown, A.M.7
Robidoux, A.8
Margolese, R.9
Kahlenberg, M.S.10
Paik, S.11
Soran, A.12
Wickerham, D.L.13
Wolmark, N.14
-
35
-
-
54049095545
-
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
-
18720362 10.1002/cncr.23776 1:CAS:528:DC%2BD1cXht1Ggu7bO
-
Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW (2008) Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113:1552-1558
-
(2008)
Cancer
, vol.113
, pp. 1552-1558
-
-
Motzer, R.J.1
Bukowski, R.M.2
Figlin, R.A.3
Hutson, T.E.4
Michaelson, M.D.5
Kim, S.T.6
Baum, C.M.7
Kattan, M.W.8
-
36
-
-
77951093888
-
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
-
20147887 10.1038/ki.2009.552 1:CAS:528:DC%2BC3cXkvVGhtr8%3D
-
Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, Canipari C (2010) Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77:809-815
-
(2010)
Kidney Int
, vol.77
, pp. 809-815
-
-
Porta, C.1
Paglino, C.2
De Amici, M.3
Quaglini, S.4
Sacchi, L.5
Imarisio, I.6
Canipari, C.7
-
37
-
-
79551701442
-
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib
-
21097692 10.1158/1078-0432.CCR-10-1828
-
van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA (2011) Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17:620-629
-
(2011)
Clin Cancer Res
, vol.17
, pp. 620-629
-
-
Van Der Veldt, A.A.1
Eechoute, K.2
Gelderblom, H.3
Gietema, J.4
Guchelaar, H.J.5
Van Erp, N.P.6
Van Den Eertwegh, A.J.7
Haanen, J.B.8
Mathijssen, R.H.9
Wessels, J.A.10
|